Pascale Missy

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio et al. · The Lancet · 2016 · 984 citations

Medicine, Molecular Medicine, Oncology +11

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

S. Couraud, Felipe Vaca‐Paniagua, Stéphanie Villar et al. · Clinical Cancer Research · 2014 · 211 citations

Medicine, Molecular Genetics, Oncology +17

Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i>-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

M. Duruisseaux, Benjamin Besse, J. Cadranel et al. · Oncotarget · 2017 · 162 citations · Full text

Medicine, Oncology, Pharmacology +14

Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).

Fabrice Barlési, Hélène Blons, Michèle Beau‐Faller et al. · Journal of Clinical Oncology · 2013 · 112 citations

Medicine, Oncology, Pathology +17

Genotype–phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease

Érick Denamur, Anne‐Lise Delezoide, Corinne Alberti et al. · Kidney International · 2009 · 93 citations

Medicine, Genetics, Molecular Genetics +14